MedTrace Logo

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

NCT03435133 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-06-10

No results posted yet for this study

Summary

The investigators propose to perform a randomized clinical trial comparing prasugrel vs. ticagrelor in 60 patients with ST elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The principal objective of the study would be analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance at 6 months

Conditions

  • ST Elevation Myocardial Infarction

Interventions

DRUG

Prasugrel

60 mg oral bolus plus oral 10 mg once daily

DRUG

Ticagrelor

180 mg oral bolus plus oral 90 mg every 12 hours daily

Sponsors & Collaborators

  • AORTICA Group

    lead OTHER

Principal Investigators

  • Pedro L Sanchez, MD, PhD · Hospital Universitario Salamanca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2018-10-30
Completion
2018-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03435133 on ClinicalTrials.gov